Pfizer vs. Teva: CGRP Patent Dispute Ends in Strategic Retreat

Case Overview

The Parties

The Patent at Issue

This landmark case involved U.S. Patent No. 11,083,724 B2, covering formulation aspects of rimegepant sulfate, a compound central to Pfizer’s migraine franchise generating hundreds of millions in annual revenue. The patent protects the CGRP receptor antagonist oral dissolving tablet formulation.

• • US11083724B2 — Pharmaceutical formulation — CGRP receptor antagonist oral dissolving tablet

The Accused Product

Teva’s ANDA product—a proposed generic version of NURTEC ODT® (rimegepant sulfate tablet)—was alleged to infringe the ‘724 Patent through the act of filing an ANDA with a Paragraph IV certification, the standard legal trigger for Hatch-Waxman infringement suits.

Legal Representation

Pfizer was represented by Morris, Nichols, Arsht & Tunnell LLP, with attorneys Dimitrios T. Drivas, Jack B. Blumenfeld, Joel L. Broussard, John P. Scheibeler, and Megan Elizabeth Dellinger. Teva was represented by Shaw Keller LLP, with Daryl L. Wiesen, Elaine H. Blais, Emily DiBenedetto, Karen Elizabeth Keller, Madeline R. Bordynoski, Magdalin Pena Jimenez, and Molly R. Grammel leading the defense.

Litigation Timeline & Procedural History

The strategic venue selection and efficient duration highlight key aspects of pharmaceutical patent litigation.

Venue selection in Delaware is standard for pharmaceutical patent litigation—the jurisdiction hosts more Hatch-Waxman cases than any other federal district, offering predictable procedure and specialized judicial familiarity with ANDA disputes.

Chief Judge Colm F. Connolly is a well-regarded Delaware jurist known for rigorous case management and significant experience in complex patent matters, including pharmaceutical IP disputes. His involvement signals this case was administered with appropriate procedural discipline.

The 603-day duration—approximately 20 months from filing to closure—is relatively efficient for pharmaceutical patent litigation, suggesting that settlement negotiations may have commenced early or that the strength of Pfizer’s patent position created favorable conditions for resolution without extended motion practice or claim construction proceedings.

The Verdict & Legal Analysis

Outcome: Stipulated Dismissal with Strategic Patent Protection

The case closed via a court-approved stipulation on January 16, 2026. The terms, as entered of record, established the following:

1. Teva’s Paragraph III Conversion: Teva agreed that, consistent with 21 U.S.C. § 355(j)(2)(A)(vii)(III), it would no longer seek FDA approval of its ANDA prior to the expiration of the ‘724 Patent—a Paragraph III certification posture that effectively delays generic market entry until the patent expires.
2. Dismissal Without Prejudice: All of Pfizer’s infringement claims regarding the ‘724 Patent and Teva’s invalidity counterclaims were dismissed without prejudice pursuant to Fed. R. Civ. P. 41(a)(1)(A)(ii) and 41(c).
3. Non-Reassertion Covenant: Pfizer committed not to reassert the ‘724 Patent against Teva’s ANDA or ANDA product, so long as Teva maintains its Paragraph III certification. This creates a conditional covenant structurally tethered to Teva’s ongoing compliance.
4. No Damages or Fee Awards: Each party bears its own fees and expenses—a neutral allocation consistent with a negotiated standstill rather than a litigated outcome.

Verdict Cause Analysis

This is a textbook Hatch-Waxman strategic resolution. No court finding on validity or infringement was required because the parties achieved their respective objectives through negotiation:

• Pfizer’s objective achieved: Market exclusivity for NURTEC ODT® through the ‘724 Patent’s expiration is protected. Teva cannot launch a generic pre-expiration without triggering new litigation risk.
• Teva’s objective preserved: By shifting to a Paragraph III posture rather than conceding infringement or validity, Teva avoids an adverse merits ruling that could prejudice it in related proceedings or future ANDA challenges.

The absence of a damages award and the “without prejudice” framing confirm that neither party was forced into a litigation corner—this was a commercially rational exit, not a capitulation.

Legal Significance

The conditional covenant not to sue is a sophisticated drafting tool that patent holders increasingly deploy in ANDA resolutions. By tethering Pfizer’s non-reassertion promise to Teva’s continued maintenance of the Paragraph III certification, the agreement creates an automatic enforcement mechanism: if Teva reverts to a Paragraph IV posture, Pfizer’s litigation rights are restored. This structure has significant precedential value for IP counsel negotiating pharmaceutical patent standstills.

The court’s retention of jurisdiction to enforce stipulation terms is also notable—it preserves judicial oversight without requiring full merits adjudication, a procedural tool frequently used in Delaware Hatch-Waxman settlements.

Strategic Takeaways

For Patent Holders:

• Filing suit promptly upon Paragraph IV certification (as Pfizer did) triggers the 30-month stay under Hatch-Waxman, creating immediate leverage even before any judicial ruling.
• Conditional covenant structures preserve reassertion rights and should be standard practice in ANDA settlements.

For Generic Manufacturers/Accused Infringers:

• Paragraph III conversion is a viable strategic retreat that avoids adverse validity or infringement findings while preserving the option to revisit market entry after patent expiration.
• Maintaining flexibility in ANDA certification posture provides meaningful negotiating currency.

For R&D Teams:

• Freedom-to-operate analyses for CGRP antagonist formulations must account for formulation-specific patents (like the ‘724 Patent) extending beyond compound patents.
• Even unlitigated-to-judgment patents can delay generic entry by years through the Hatch-Waxman framework.

Industry & Competitive Implications

The CGRP antagonist market—anchored by branded products including NURTEC ODT®, Ubrelvy, and Aimovig—represents one of the most actively litigated pharmaceutical spaces of the 2020s. Pfizer’s aggressive patent assertion posture across multiple ANDA filers (including the related Case No. 1:24-cv-00621, referenced in the stipulation filing) signals a layered IP strategy designed to maximize exclusivity across the ‘724 Patent’s lifespan.

For Teva, this resolution is consistent with a broader industry pattern: large generic manufacturers will accept delayed market entry when faced with well-constructed pharmaceutical patent portfolios, particularly where the litigation risk of an adverse invalidity finding could affect other pending ANDAs or licensing negotiations.

For companies operating in the oral dissolving tablet or CGRP therapeutic space, this case reinforces that formulation patents can carry substantial market exclusivity value independent of the underlying active compound’s patent status. R&D and regulatory teams should conduct targeted FTO reviews covering dosage form, salt form, and manufacturing process patents—not just composition-of-matter claims.